This department store operator went public in late 2010 and delivered decent financial results for a couple of years but is now being hit by the sharp slowdown in retail spending. 

Gordmans earned $1.30 a share in fiscal 2012, but since then earnings per share (EPS) have slid to a recent $0.41. Analysts expect even lower profits for the current fiscal year. As a result, shares have been in a nearly two-year downdraft.

The steady slide has its roots in a series of poor merchandising selections for this retailer, which is known for sharply discounted prices on slightly out-of-favor goods. Gordmans’ board has done what any retailer in this position should do: They’ve brought in more savvy merchandisers who aim to fill the stores with a much more compelling line of goods. (A search for a new CEO is underway as well.) 

Analysts at Cannacord/Genuity think “a new merchandising team will build better misses’ and men’s assortments, and this will drive improving results.” But that’s not the main reason they think this stock will double to their $10 target price. Instead, it’s the fact that share of Gordmans trade at unfathomably low valuations. “Shares trade at 0.2x FY14E EV/sales (ratio of enterprise value to expected 2014 sales), which we believe is a going-out-of-business valuation.” 

But Gordmans isn’t going out of business. This retailer is expected to report results next week, and should report solid cash balances as too-high inventories have since been converted into cash. Simply moving this stock up to a 0.4 times enterprise value-to-sales ratio would still leave this stock as one of the lowest-valued in retail.

It’s been a lousy stretch for biotech and medtech companies, especially those that had the bad timing to conduct an IPO in the midst of a recent massive sell-off. This developer of leading-edge wound care dressings initially saw its shares move up to $19, but now trade for around $11. Yet analysts think MediWound has solid growth prospects.

MediWound’s lead product is NexoBrid, a gel enzyme that “may usher in a new paradigm for the treatment of third-degree burns,” predict analysts at BMO Capital. This gel allows for a much cleaner preparation of the wound — without much blood loss — before skin grafts can be applied. Already approved for sale in Europe, the gel is in Phase III trials in the U.S. 

BMO’s analysts predict peak annual sales for NexoBrid of around $275 million, and in tandem with other products in the development pipeline, total sales could top $400 million annually. To be sure, profitability is a few years away, so BMO’s analysts looked out to 2020 sales and profit levels, discounted back to the current time, to derive their $20 price target, which represents 80% upside. 

Credit Suisse’s Brice Nudell has a more modest $18 price target. While BMO mostly focuses on the short-term opportunities for NexoBrod, Nudell is even more intrigued by MediWound’s EscharEX, which is earlier in the clinical trial process and wouldn’t hit the market until later this decade, if approved. He notes that Santyl, the current product used in burn care, generates $270 million in annual sales, and “EscharEx appears to be more effective than Santyl in burn,” he adds.

Web video remains a fast-growing category, with video streaming volumes continuing to rise at more than 20% each year. Brightcove provides all the tools needed for companies to host and stream videos. 

This company garnered a considerable amount of buzz a few years ago, and after its early 2012 IPO, shares eventually moved up into the $20s. These days, thanks to slowing growth, shares languish in the single digits.

Each year, Brightcove’s top-line growth has fallen by about 10 percentage points, from around 45% in 2011 to an expected mid-teens rate this year. Of equal concern, the company has never been profitable. 

Yet first-quarter results now suggest that investors have grown too pessimistic. First-quarter sales grew 26% from a year ago, to $31 million, and the company added 61 new customers, the strongest quarterly showing in its history. Pacific Crest Securities’ conclusion: “Growth is returning to Brightcove.”

And these analysts now think shares are too cheap, trading at just twice 2015 sales. They figure that growth investors will return and bid shares back up to a 3 times sales multiple, “which is still a major discount to peers.” That equates to a $16 price target, implying 90% upside.